The ABPI has signed a declaration, in partnership with more than 80 leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as international and domestic industry bodies, to call on governments and industry to work in parallel in taking comprehensive action against drug-resistant infections.
The joint declaration launched at the World Economic Forum in Davos, Switzerland sets out, for the first time, how governments and the life sciences industry need to work together to support sustained investment in the new products needed to beat the challenges of rising drug resistance.
The declaration supports the ongoing work in the UK on tackling the challenges with AMR which included funding commitments in the most recent Spending Review. The ABPI continues to work closely with the AMR Review team and relevant government departments in England, Scotland, Wales and Northern Ireland to seek a strong and coherent response to AMR.
Dr Virginia Acha, Executive Director for Research and Medical Innovation, said:
"When David Cameron announced the AMR Review work in July 2014, he called for 'a stronger, more coherent global response, with nations, business and the world of science working together to up our game in the field of antibiotics'. With this global Declaration of Support for Combating AMR, industry has given that response. It is up to us all to make sure that delivers new solutions to address AMR for patients everywhere."